Briefing on the Fundamentals of Seagen

By Chris Stiles • Wednesday, September 27 12:09 • Permanent Link

More and more people are talking about Seagen over the last few weeks. Is it worth buying the Biotechnology stock at a price of $212.64? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Seagen has moved 54.0% over the last year, and the S&P 500 logged a change of 15.0%
SGEN has an average analyst rating of hold and is -5.42% away from its mean target price of $224.83 per share
Its trailing earnings per share (EPS) is $-3.89
Seagen has a trailing 12 month Price to Earnings (P/E) ratio of -54.7 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-1.4 and its forward P/E ratio is -151.9
The company has a Price to Book (P/B) ratio of 15.24 in contrast to the S&P 500's average ratio of 2.95
Seagen is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $-356108864, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.